The pharmaceutical industry is in a frenzy over the recently released list of the drugs subject to price negotiation under the Inflation Reduction Act of 2023 (IRA) and the Act’s potential impact on profits. But an even bigger force… Continue Reading
Supplier Spotlight® highlights the unique skill sets and service offerings from organizations who are part of our CONNECTED COMMUNITY™. Below is an interview with Market Access & Pricing Strategy (MArS), the German-speaking market access experts. Tell us about MArS Market Access… Continue Reading
Consequential prescription drug pricing decisions in the United States increasingly involve high-stakes interactions between the manufacturer and the Institute for Clinical and Economic Review (ICER). Continue Reading
Written By: Americans spend more on prescription drugs than anyone else in the world. In a move to address this, CVS Caremark announced in August that it would allow self-funded insurers to exclude from their plan any drug launched at… Continue Reading
Written by Swarali Tadwalkar, MPH, Guest Blogger and Research Intern at HealthEconomics.Com Drug prices are the fastest-growing part of healthcare costs, and everyone – from patients, to physicians, policy-makers, and pharmaceutical companies – are grappling with price-setting and drug value assessment.… Continue Reading
